The home of the Audio Journal of Oncology

Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

AudioMedica News
AudioMedica News
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
/
Stephen Jones
Stephen Jones

STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071213_stephen_jones.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality